Strategic partnership Inpart is the result of a strategic merger between a leading biopharma partnering platform and a specialized academia-industry matchmaking platform, creating a broader opportunity to offer end-to-end collaboration solutions to pharma, biotech, and academic customers.

Market expansion The combined platform targets biopharma, biotech, and academia, enabling faster deal-making and collaboration management, which can be pitched to organizations looking to accelerate translation from research to market.

Financial scale Reported revenue in the mid hundreds of millions suggests substantial deal flow and budget availability for enterprise partnerships, with potential upsell opportunities in enterprise-grade collaboration and analytics offerings.

Tech-enabled With a modern tech stack including OpenAI, Claude, Atlassian, and identity and collaboration tools, there is room to tailor AI-assisted partner matching, due diligence, and workflow automation for prospective customers.

Strategic partnerships Recent collaboration with Evaluate to optimize biopharma dealmaking signals a pattern of expanding ecosystem partnerships, presenting a recurring entry point for co-sell and channel partnerships with research analytics providers and industry networks.